Accessibility Menu
Hikma Pharmaceuticals Plc logo

Hikma Pharmaceuticals Plc(OTC) HKMPY

Market Cap$4.71BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2011)+148%
5 Year-28%
1 Year-2%
1 Month+12%
$45.36
+0.00%
+0.00Today
Hikma Pharmaceuticals Plc last closing stock price
MetricPriceDate
Last closeUSD 45.362026-08-14
Hikma Pharmaceuticals Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.86%USD 46.212026-08-06
1 month+11.85%USD 40.552026-07-15
3 month+15.7%USD 39.202026-05-15
Year to date+11.31%USD 40.752025-12-31
1 year-1.86%USD 46.222025-08-14
3 year-12.15%USD 51.632023-08-15
5 year-27.56%USD 62.612021-08-11
Since inception+148.37%USD 18.262011-03-28

Hikma Pharmaceuticals Plc Financials at a Glance

Market Cap

$4.71BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$6.63B

Net Income (TTM)

$756.00M

EPS (TTM)

$3.52

P/E Ratio

12.63

Dividend

$1.68

Beta (Volatility)

0.36 (Low)

Price

$45.36

Volume

190

Open

$45.36

Previous Close

$45.36

Daily Range

$45.36 - $45.36

52-Week Range

$31.80 - $50.56

Estimated Earnings Date

Feb 24, 2026

HKMPY News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Hikma Pharmaceuticals Plc

Hikma Pharmaceuticals PLC is a global pharmaceutical company specializing in the development, production, and distribution of a diverse range of generic, branded, and in-licensed medicines. The company operates through three main divisions: Injectables, Generics, and Branded products, serving various therapeutic areas across multiple international markets.

Products and Services
  • Injectable medications primarily for hospital use
  • Oral and non-injectable generic formulations for retail
  • Branded generic drugs and licensed products for consumers and hospitals
Growth Outlook
  • Revenue of $1.73 billion in Q2 2026, showing strong demand
  • Net income increased to $223 million in Q2 2026, reflecting profitability
  • Operating income margin improved to 20.8% in Q2 2026, indicating operational efficiency
Financial Highlights
  • Trailing twelve months (TTM) revenue of $6.67 billion, demonstrating consistent growth
  • Dividend yield of 3.77%, providing attractive returns to shareholders
  • Current ratio of 1.98, indicating strong liquidity position
Hikma Pharmaceuticals PLC has established a robust presence in the pharmaceutical industry, focusing on high-demand therapeutic areas such as anti-infectives, oncology, and cardiovascular health. The company's diverse product portfolio and strategic international operations position it well for future growth. Recent financial performance highlights a solid revenue base and profitability, with a notable increase in net income and operating margins. The strong liquidity and attractive dividend yield further enhance the investment appeal of Hikma Pharmaceuticals, making it a noteworthy consideration for potential investors.
AI Generated • Aug 15, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

9,400

CEO

Riad Mishlawi

Website

www.hikma.com

Headquarters

London, GL W1S 2HR, GB

HKMPY Financials

Key Financial Metrics (TTM)

Gross Margin

40.88%

Operating Margin

19.41%

Net Income Margin

11.31%

Return on Equity

15.05%

Return on Capital

13.57%

Return on Assets

6.59%

Earnings Yield

7.92%

Dividend Yield

3.70%

Payout Ratio

46.65%

Stock Overview

Market Cap

$4.71BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

103.90M

Volume

190

Avg. Volume

427.968

Financials (TTM)

Gross Profit

$2.73B

Operating Income

$1.16B

EBITDA

$1.67B

Operating Cash Flow

$878.62M

Capital Expenditure

-$411.99M

Free Cash Flow

$466.63M

Cash & ST Invst.

$289.00M

Total Debt

$1.96B

Hikma Pharmaceuticals Plc Performance Analysis

Hikma Pharmaceuticals Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 2,515,446,660-1.5%
20232023-12-31USD 2,886,143,70614.7%
20242024-12-31USD 3,128,315,8068.4%
20252025-12-31USD 3,356,826,1807.3%
Hikma Pharmaceuticals Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-0.7%
Q22025-06-306.4%
Q42025-12-311.6%
Q22026-06-302.6%
Hikma Pharmaceuticals Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 1.67-53.8%
20232023-12-31USD 1.722.7%
20242024-12-31USD 3.2187.4%
20252025-12-31USD 3.6212.6%
Hikma Pharmaceuticals Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-41.6%
Q22025-06-3081.4%
Q42025-12-31-30.8%
Q22026-06-3037.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$1.73B

+10.1%

Gross Profit

$727.86M

-3.7%

Gross Margin

42.13%

N/A

Market Cap

$4.71BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$501.30K

N/A

Employees

9,400

N/A

Net Income

$222.96M

-1.3%

EBITDA

$481.91M

+12.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$289.00M

+11.2%

Total Debt

$1.96B

+53.4%

Accounts Receivable

$1.12B

+19.6%

Inventory

$1.18B

+25.6%

Long Term Debt

$1.75B

+65.2%

Short Term Debt

$204.00M

-5.1%

Return on Assets

6.59%

N/A

Return on Invested Capital

14.83%

N/A

Free Cash Flow

$46.99M

-63.6%

Operating Cash Flow

$168.97M

-14.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
DNPUFSumitomo Pharma Co., Ltd.
$8.41+0.00%
ZLDPFZealand Pharma A/S
$52.68+1.71%
GZPHFGuangzhou Baiyunshan Pharmaceutical Holdings Company Limited
$2.34+0.00%
OPHLFOno Pharmaceutical Co., Ltd.
$14.71+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.23+0.09%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.76+0.01%
ONDSOndas
$9.24+0.04%
SPCXSpace Exploration Technologies
$140.00-0.01%

Questions About HKMPY

What is the current price of Hikma Pharmaceuticals Plc?

Hikma Pharmaceuticals Plc is trading at $45.36 per share.

What is the 52-week range for Hikma Pharmaceuticals Plc?

Over the past 52 weeks, Hikma Pharmaceuticals Plc has traded between $31.80 and $50.56.

How much debt does Hikma Pharmaceuticals Plc have?

As of the most recent reporting period, Hikma Pharmaceuticals Plc reported total debt of $1.60B.

How much cash does Hikma Pharmaceuticals Plc have on hand?

Hikma Pharmaceuticals Plc reported $328.00M in cash and cash equivalents in its most recent financial results.

What is Hikma Pharmaceuticals Plc’s dividend yield?

Hikma Pharmaceuticals Plc currently has a dividend yield of 3.70%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services